Roivant Sciences(NASDAQ) ROIV

Roivant Sciences Ltd. helps patients by developing new medicines for serious diseases. The company uses focused teams to advance treatments for skin and immune conditions. These medicines aim to solve health problems that have few other options.

Pills, Pipelines, and Platforms

• Immunology Candidates: Antibody treatments for autoimmune diseases where the immune system attacks the body, including trials for Graves' disease and myasthenia gravis.
• Inflammatory Medicines: Small molecule drugs like brepocitinib designed to treat dermatomyositis, a condition causing painful skin rashes and muscle weakness.
• Pulmonary Treatments: Inhaled therapies for pulmonary hypertension, which is high blood pressure in the lungs often linked to lung scarring.
• Health Technology: Data and software platforms used to identify new drug candidates and improve clinical trial efficiency.

Strategic Growth and New Deals

• Sold the subsidiary Dermavant in 2024 while keeping rights to future milestone payments and royalties from its products.
• Secured a $2.25 billion patent settlement with Moderna in 2026, with an initial $950 million payment received by its subsidiary Genevant.
• Authorized $1.0 billion for share repurchases in 2025 to return capital to shareholders as the business matures.
• Initiated Phase 3 clinical trials for brepocitinib in cutaneous sarcoidosis, a rare inflammatory skin disease, following positive Phase 2 results.

A Different Way to Innovate

Roivant operates through Vants, which are independent subsidiary companies built around specific medicines or technologies. This structure allows the company to develop many different drugs at once while keeping development teams focused and efficient.

Recent Financial Results

• Revenue was $1.4 million for the three months ended June 30, 2026.
• Market capitalization reached $25.5 billion in the first quarter of 2026, up 232.7% year over year.
• Research and development expenses increased by $49.1 million to $202.0 million for the three months ended June 30, 2026.
• The company held $3.8 billion in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Net loss attributable to the company was $189.8 million for the three months ended June 30, 2026.

Evolution of the Business

Roivant has grown from a drug incubator into a late-stage biopharmaceutical firm with a diverse pipeline. Its decentralized model and strong cash position help it acquire and develop new therapies for patients with limited options.